BioMark Diagnostics Inc
CNSX:BUX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.22
0.54
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CA |
B
|
BioMark Diagnostics Inc
CNSX:BUX
|
50.4m CAD |
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
31.5B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
19.4B USD |
Loading...
|
|
| FR |
|
Biomerieux SA
PAR:BIM
|
11.5B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
13.6B USD |
Loading...
|
|
| US |
C
|
Caris Life Sciences Inc
NASDAQ:CAI
|
7.2B USD |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.8T KRW |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.8B CNY |
Loading...
|
|
| CH |
|
Siegfried Holding AG
SIX:SFZN
|
4.3B CHF |
Loading...
|
|
| IT |
|
DiaSorin SpA
MIL:DIA
|
3.9B EUR |
Loading...
|
|
| UK |
|
Abcam PLC
LSE:ABC
|
2.8B GBP |
Loading...
|
Market Distribution
| Min | -4 710 029.9% |
| 30th Percentile | -65.8% |
| Median | -2.4% |
| 70th Percentile | 11% |
| Max | 71 100% |
Other Profitability Ratios
BioMark Diagnostics Inc
Glance View
BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for BioMark Diagnostics Inc is -1 231.3%, which is above its 3-year median of -1 232.1%.
Over the last 3 years, BioMark Diagnostics Inc’s Operating Margin has increased from -2 031% to -1 231.3%. During this period, it reached a low of -2 031% on Jun 30, 2022 and a high of -988.5% on Mar 31, 2024.